The FDA has approved the medication Mounjaro to help lower the risk of major cardiovascular events in high-risk patients with type 2 diabetes.

The U.S. Food and Drug Administration has approved Mounjaro to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk. The approval follows results from the SURPASS-CVOT clinical trial, which compared the medication head-to-head against Trulicity. Eli Lilly, the manufacturer of Mounjaro, announced the regulatory decision on August 28.

Clinical Trial Results and Methodology

The SURPASS-CVOT study was the largest and longest trial of tirzepatide to date, involving more than 13,000 participants across 30 countries. The study utilized a median follow-up period of 4 years. Researchers found that Mounjaro was noninferior to Trulicity, a GLP-1 medication already known for cardiovascular benefits. Data showed that major cardiovascular events occurred in 12.2% of participants taking Mounjaro, compared with 13.1% of those taking Trulicity, representing an 8% lower relative risk.

Mechanism and Clinical Perspective

Mounjaro functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. According to Dr. Randy Gould, the medication helps lower blood sugar by signaling the pancreas to release insulin after eating and slowing digestion. These actions may reduce systemic inflammation and endothelial dysfunction, potentially helping to stabilize arterial plaques. Medical experts noted that this approval provides clinicians with an additional treatment option that addresses multiple health concerns simultaneously. While the findings are considered encouraging, Dr. Rigved Tadwalkar cautioned that the study focused on a very high-risk population with established cardiovascular disease, and results may not necessarily apply to every patient taking the medication.